General
Preferred name
ixazomib
Synonyms
MLN2238 ()
MLN 2238 ()
Ixazomib (MLN2238) ()
Ninlaro ()
MLN-9708 FREE BASE ()
MLN-2238 ()
P&D ID
PD003323
CAS
1072833-77-2
Tags
nuisance
covalent binder
drug
available
Approved by
PMDA
EMA
FDA
First approval
2015
Drug Status
investigational
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Ixazomib is the first approved oral proteasome inhibitor. Ixazomib reversibly inhibits 20S proteasome activity. Like , ixazomib primarily inhibits the chymotrypsin-like (β5) proteolytic site within the 20S proteasome, but its pharmacokinetics, pharmacodynamics, and antitumor activity are superior to those of bortezomib .
(GtoPdb)
DESCRIPTION
inhibitor of 20S proteasome at the chymotrypsin-like proteolytic (beta-5) site
(Informer Set)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
4
Organisms
0
Compound Sets
25
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CovalentInDB
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Informer Set
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Nuisance compounds in cellular assays
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
31
Molecular Weight
360.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
1
Aromatic Ring Count
1
cLogP
1.27
TPSA
98.66
Fraction CSP3
0.43
Chiral centers
1.0
Largest ring
6.0
QED
0.55
Structural alerts
1
Protein disruption
Proteosome inhibition
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Target
PSMB5
20S proteasome
caspase-like (??1)
Proteasome
Autophagy,Proteasome
Compound status
clinical
Pathway
Proteases/Proteasome
Ubiquitination
Apoptosis
Autophagy
Metabolic Enzyme/Protease
Indication
multiple myeloma
MOA
Proteasome inhibitor
Source data
